Researchers have developed a novel method to enhance the ability of mesenchymal stromal cells (MSCs) to generate cartilage tissue by adding ascorbic acid (AA) during MSC expansion. The research also ...
In the field of Regenerative Medicine, the preclinical and clinical research on multipotent adult stem cells, and in ...
RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication. RYONCIL is the first FDA-approved therapy for children aged 2 months and older, including adolescents and teenagers ...
"The Phase 3 trial in adults with SR-aGvHD will position Ryoncil ® as the earliest treatment regimen for severe disease after steroid resistance." Mesoblast (the Company) is a world leader in ...
3don MSN
First in-human study finds novel immune cell therapy is safe and effective in advanced lymphoma
In a first-in-human study, researchers at The University of Texas MD Anderson Cancer Center observed strong responses and early signs of antitumor activity in patients with difficult-to-treat ...
To ensure that no patient is left behind in receiving this potentially life-saving therapy, Mesoblast has established a patient access hub termed MyMesoblast™, where Ryoncil ® is available for ...
The successful clinical validation of AlloHeme represents a key milestone in CareDx's Transplant+ strategy, expanding the Company's precision medicine capabilities into cell therapy, hematology, and ...
Stem cell therapy biotech PrimeGen US is taking the less-traveled special purpose acquisition company (SPAC) route to the ...
Ryoncil ® gross sales for the quarter were US$35 million, a 60% increase on the prior quarter ended September 30, 2025, and net revenues were US$30 million. 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results